Volume 0 - Accepted Manuscripts                   Physiol Pharmacol 2021, 0 - Accepted Manuscripts: 0-0 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Miraee S, Farhadi M, Jameie S B, Najafie S. The protective effects of apigenin on OLN-93 cellular model of cerebral stroke: A cellular model study. Physiol Pharmacol. 2021;
URL: http://ppj.phypha.ir/article-1-1676-en.html
Abstract:   (101 Views)
SIMULATION OF CHLORIDE (CL) AND ALL DISSOLVED SOLIDS (TDS) IN WATER USING THE CONJOINED WAVELET ANFIS NETWORK IN COMPARISON WITH THE CONJOINED WAVELET ANN Cerebral stroke is known to be the third most common cause of death in the world. To study the pathophysiology and effects of the therapeutic agents on stroke, the cellular model of stroke recently was used more. ONL-93 oligodendrocyte like the cell is known as an appropriate model to study the role of glial cells in stroke.  Apigenin is a flavonoid that has neuroprotective and neurogenic effects, therefore, the purpose of this study was to investigate the role of apigenin flavonoid on the OLN-93 cell line in terms of oxygen and glucose deprivation in the cellular stroke model. The cells were divided into experimental, negative, and positive control groups. Then, MTT, ROS, Annexin & PI, and western blotting assays were performed to evaluate the viability and apoptosis. The results showed that there was a significant increase in the number of live cells following administration of 1 μM of apigenin (P <0.05) in experimental groups and also, there was a significant difference in the number of live cells between two doses of 1μM and 0.75 μM of the apigenin. The amount of ROS produced at a concentration of 1μM apigenin was a significant decrease compared to the positive control group and apoptotic cells also decreased significantly. The results for the expression of P53 protein showed a significant reduction in experimental groups.
Types of Manuscript: Original Research | Subject: Neurodegenerative diseases

Manuscript [PDF 616 KB]  (14 Download)
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.